IP Library Granted Patent US 11,845,962
Granted Patent B2
US 11,845,962 · App. 17/041,578 · Granted Dec 19, 2023

Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells

Inventors: Yi Hong (Shanghai, CN); Ting Yan (Shanghai, CN); Jiangguo Ying (Shanghai, CN); Haojie Zhang (Shanghai, CN); Luyi Zhang (Shanghai, CN); Li Zhang (Shanghai, CN)
Assignee: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
C12N7/00C12N15/86C12N2740/15043C12N2740/15051C12N2740/16043C12N2740/16051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,845,962
App. No.
17/041,578
Granted
Dec 19, 2023
Kind
B2
Abstract

Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (1) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.

Claims (39)

1. A method for producing lentivirus using serum-free suspension cells, which comprises the steps of:

(a) providing a seed solution of packaging cells for the production of lentivirus, wherein the packaging cells are packaging cells that grow in suspension;

(b) inoculating the seed solution in a first culture medium placed in a culture container to obtain a first culture, wherein the first culture medium is a serum-free cell culture medium, and the inoculation density is 1×10 6 -5×10 6 cells/ml, and the volume of the first culture medium is 3-100 liters;

(c) carrying out subculture of the packaging cells of the first culture, wherein the subculture conditions are set at a temperature of 30-38° C., a dissolved oxygen concentration of 35-55%, a CO 2 concentration of 2-10% and a pH of 6.9-7.4, and monitoring the real-time pH value of the first culture during the subculture process, and controlling dissolved oxygen and/or CO 2 concentrations based on the real-time pH value to maintain the pH between 6.9-7.4;

(d) starting a liquid change operation when liquid change trigger conditions are met,

wherein the liquid change trigger conditions comprise:

(s1) the real-time pH is ≤6.9 or ≤7.0 or ≤7.05;

(s2) the real-time pH value is still showing a downward trend by adjusting the concentration of oxygen, air, nitrogen and/or CO 2 ; and

(s3) the subculture time is ≥72 hours;

wherein, the liquid change operation comprises: discharging the cell-free supernatant in the culture from the culture container, wherein the volume of the culture before discharging the supernatant is Vq1, while the volume of the culture after discharging the supernatant is Vh1, and the ratio of Vq1/Vh1 is 3-15; then, adding the culture medium to the culture container to form a packaging cell culture;

(e) repeating steps (c) and (d) n times, wherein n is 1, 2, or 3;

(f) starting a transfection operation when transfection trigger conditions are met,

wherein, the transfection trigger conditions comprise:

(t1) the total number of cells is 0.05-2×10 11 cells;

(t2) the cell density is 0.5-5×10 6 cells/ml;

(t3) the cell viability rate is ≥90%; and

(t4) the total culture time is ≥72 hours;

wherein, the transfection operation comprises: mixing a production plasmid used for producing the lentivirus with a transfection reagent, and adding the mixture to the culture container for introduction to the packaging cells to form transfected packaging cells;

(g) optionally carrying out post-transfection liquid change;

(h) culturing the transfected packaging cells, wherein the culture conditions are set at a temperature of 30-37° C., a dissolved oxygen concentration of 35-55%, a CO 2 concentration of 2-10% and a pH of 6.9-7.4, and monitoring the real-time pH value of the first culture during the subculture process, and controlling dissolved oxygen and/or CO 2 concentrations based on the real-time pH value to maintain the pH between 6.9-7.4;

(i) starting a harvest and liquid change operation when liquid change trigger conditions are met,

wherein the liquid change trigger conditions comprise:

(s1) the real-time pH is ≤6.9;

(s2) the real-time pH value is still decreasing by adjusting the concentration of oxygen, air, nitrogen and/or CO 2 ; and

(s3) the subculture time is ≥72 hours;

wherein the liquid change operation comprises: recovering the cell-free virus-containing feed liquid from the culture, wherein the volume of the culture before recovering the feed liquid is Vq2, while the volume of the culture after recovering of the supernatant is Vh2, and the ratio of Vq2/Vh2 is 3-15;

(j) repeating steps (h) and (i) m times, wherein m is 1, 2, or 3, and before repeating, adding culture medium to the culture container to form a transfected cell culture;

(k) mixing the recovered liquids from each recovery to obtain a combined virus-containing supernatant; and

(l) purifying the mixed virus-containing supernatant to obtain a purified lentiviral vector;

wherein, the culture medium used in all the above steps is a serum-free cell culture medium.

2. The method of claim 1 , wherein in step (c) and/or (h), the culture is performed under a shaking condition.

3. The method of claim 1 , wherein in step (c) and/or (h), the pH is maintained between 7.0 and 7.35.

4. The method of claim 1 , wherein in step (d) and/or (i), the ratio of Vq1/Vh1 is 5-10.

5. The method of claim 1 , wherein the total time of steps (c), (d) and (e) is 72-216 hours.

6. The method of claim 1 , wherein in step (f), the multi-plasmid transfection comprises three-plasmid transfection and four-plasmid transfection.

7. The method of claim 1 , wherein the culture container is a disposable culture container.

8. The method of claim 1 , wherein the total number of viruses contained in the mixed virus-containing supernatant is 1×10 12 Tu.

9. The method of claim 1 , wherein the packaging cells are human embryonic kidney epithelial cells.

10. The method of claim 1 , wherein in step (1), the purification comprises: ultrafiltration and chromatography.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67128 FRAME: 44. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 7, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067334/0083 →
CHANGE OF NAME Recorded Apr 16, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067128/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 061579/0838 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2020
From: HONG, YI; YAN, TING; YING, JIANGGUO; ZHANG, HAOJIE; ZHANG, LUYI; ZHANG, LI
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 053985/0904 →
Priority Claims (1)
CN 201810273392.7 · Mar 29, 2018 · national
Continuity (1)
Related Publication 20210363497A1 · Nov 25, 2021